Scancell Holdings Plc (SCNLF)
OTC PINK OTC PINK Primary 
Melanoma trial success moves Scancell to phase III - ICYMI
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) CEO Phillip L'Huillier talked with Proactive about new clinical data from its phase two melanoma study, known as the SCOPE trial, featuring its lead ImmunoBody candidate, iSCIB1+. L'Huillier highlighted that the trial has achieved the objectives set out for it, confirming the parameters for the company's upcoming registrational phase three study.
Is Scancell nearing 'significant value crystallisation point'?
There's been an odd reaction to some encouraging news from Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF), with the shares barely flickering this week. The company updated the market with more supportive data from a trial of its drug for people with hard-to-treat melanoma, a common skin cancer.
Scancell Holdings plc (SCNLF) Discusses SCOPE Phase II Data: iSCIB1+ Shows Improved Progression-Free Survival in Advanced Melanoma Transcript
Scancell Holdings plc (SCNLF) Discusses SCOPE Phase II Data: iSCIB1+ Shows Improved Progression-Free Survival in Advanced Melanoma Transcript
Scancell draws broker praise after fresh melanoma data and FDA progress
Panmure Liberum said Scancell Holdings PLC's (AIM:SCLP, OTC:SCNLF) latest clinical update has strengthened the case for its cancer vaccine programme, arguing that “significant value is building” as the company moves toward a pivotal phase III trial. The broker reiterated its buy rating and 32p target price following new readouts from the phase II SCOPE study and encouraging feedback from regulators, including the US Food and Drug Administration.
Scancell hails improved survival in melanoma study as it readies for phase III
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) has reported another encouraging set of mid-stage trial results for its melanoma vaccine candidate iSCIB1+, saying the treatment continues to show better outcomes than today's standard therapies and is shaping up for late-stage testing next year. Fresh data from the phase II SCOPE trial suggest the therapy, when combined with the immunotherapy drugs ipilimumab and nivolumab, produced a progression-free survival rate of 74% at 16 months in a genetically defined group of patients.
Scancell hails promising melanoma trial results as plans accelerate for next stage
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) said on Friday that new data from its mid-stage cancer trial suggest its experimental therapy could outperform existing treatments for advanced melanoma, the most serious form of skin cancer. The Oxford-based biotechnology company presented the results at a major immunotherapy conference in the United States, saying its iSCIB1+ treatment, a DNA-based immunotherapy designed to boost the body's immune response against tumours, showed encouraging efficacy and safety.
Scancell lines up its next move after promising vaccine data
Scancell Holdings PLC's (AIM:SCLP, OTC:SCNLF) prelims earlier brought into sharp focus the significant clinical progress made in the last 12 months, as well as spelling out what investors should expect next. Its preparations follow encouraging results from its melanoma vaccine trial in July, and Panmure Liberum, its house broker, reckons the next 18 months will be busy.
Scancell eyes key cancer milestones and data
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) is gearing up for a pivotal period with fresh data due from its cancer trials later in 2025 and preparations underway for larger studies that could pave the way for regulatory approval. The Oxford-based biotech is developing therapies that harness the body's immune system to fight tumours.
Scancell: Broker raises price target after impressive cancer vaccine results
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) has reported impressive interim data from its SCOPE cancer vaccine trial, prompting Panmure Liberum to upgrade its price target to 32p from 24p. The biotech company, which specialises in therapeutic cancer vaccines, reported significantly improved response rates from the SCOPE trial involving 47 patients across three cohorts, substantially outperforming current standard treatments.
Scancell reports strong phase II results for melanoma immunotherapy
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) has reported what it described as 'strong' phase II results for its experimental immunotherapy, iSCIB1+, showing a marked improvement in outcomes for patients with late-stage melanoma when added to standard treatments. The UK-based life sciences group announced that its SCOPE trial, which is assessing the Immunobody DNA-based therapy in combination with established checkpoint inhibitors, showed an overall response rate of 69% in patients with a specific genetic marker.
Scancell gears up for summer data readouts
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) has some big dates on the calendar. July will bring results from the first three groups of its phase II SCOPE trial for advanced melanoma, and it's already started dosing patients in the final group.
Scancell shares rise 6% as melanoma trial progresses with new dosing strategy
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) shares rose 6% on Wednesday after the company began dosing patients in a new arm of its Phase II melanoma trial, marking a key step in the development of its next-generation cancer immunotherapy. The new cohort, part of the ongoing SCOPE study, will test intradermal delivery and a faster dosing schedule of Scancell's iSCIB1+ Immunobody therapy in combination with checkpoint inhibitors.
